Palvella Therapeutics (NASDAQ:PVLA) Upgraded to “Strong-Buy” at Chardan Capital

Chardan Capital upgraded shares of Palvella Therapeutics (NASDAQ:PVLA) to a strong-buy rating in a research report sent to investors on Tuesday,Zacks.com reports.

Other analysts also recently issued research reports about the stock. HC Wainwright reissued a “buy” rating and set a $270.00 target price on shares of Palvella Therapeutics in a research report on Wednesday, July 22nd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Palvella Therapeutics in a research note on Monday, June 29th. Stephens reissued an “overweight” rating and issued a $220.00 price objective on shares of Palvella Therapeutics in a research report on Thursday, May 21st. Finally, Wall Street Zen downgraded shares of Palvella Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, April 11th. Two analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $199.53.

Palvella Therapeutics Stock Performance

Shares of PVLA opened at $150.19 on Tuesday. Palvella Therapeutics has a fifty-two week low of $34.57 and a fifty-two week high of $161.38. The company has a market capitalization of $2.15 billion, a PE ratio of -36.02 and a beta of -0.20. The stock has a fifty day moving average of $129.69 and a two-hundred day moving average of $118.14.

Palvella Therapeutics (NASDAQ:PVLA) last released its earnings results on Thursday, May 7th. The company reported ($1.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.90) by ($0.30). As a group, equities research analysts forecast that Palvella Therapeutics will post -5.26 earnings per share for the current fiscal year.

Insider Activity at Palvella Therapeutics

In other news, COO Kathleen Goin sold 4,302 shares of the company’s stock in a transaction on Wednesday, June 17th. The shares were sold at an average price of $110.73, for a total value of $476,360.46. Following the completion of the transaction, the chief operating officer directly owned 2,154 shares in the company, valued at approximately $238,512.42. This represents a 66.64% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 17.20% of the company’s stock.

Institutional Investors Weigh In On Palvella Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in PVLA. KBC Group NV acquired a new stake in shares of Palvella Therapeutics during the first quarter valued at about $28,000. Group One Trading LLC lifted its stake in shares of Palvella Therapeutics by 151.5% in the fourth quarter. Group One Trading LLC now owns 332 shares of the company’s stock worth $35,000 after acquiring an additional 200 shares in the last quarter. Russell Investments Group Ltd. acquired a new stake in Palvella Therapeutics during the 3rd quarter valued at approximately $36,000. China Universal Asset Management Co. Ltd. acquired a new position in Palvella Therapeutics in the fourth quarter worth about $167,000. Finally, Keybank National Association OH bought a new position in Palvella Therapeutics in the 1st quarter worth approximately $228,000. Hedge funds and other institutional investors own 40.11% of the company’s stock.

Palvella Therapeutics Company Profile

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.